Acticor Biotech SAS operates as a clinical stage biopharmaceutical company that develops drugs for the treatment for acute thrombotic diseases. The company develops glenzocimab, a humanized monoclonal antibody fragment that targets platelet glycoprotein VI. It's product glenzocimab is in Phase 2/3 clinical trial, as well as completed Phase 1b/2a for the treatment of acute ischemic stroke; and Phase 2/3 clinical trial for treatment of cerebrovascular accidents in emergency situations, as well as completed Phase 2 clinical trial for treating acute respiratory distress syndrome (covid-19). The company has collaboration agreement with the University of Birmingham for Phase 2b clinical trials of glenzocimab in treating heart attacks. The company was incorporated in 2013 and is headquartered in Paris, France.
Frequently asked questions
What sector does Acticor Biotech SAS (ALACT) operate in?
Acticor Biotech SAS belongs to the Communication Services sector and operates in the Biotechnology industry.
What is Acticor Biotech SAS (ALACT) current stock price?
As of the latest data, Acticor Biotech SAS stock price is €0.25, with a previous close of €0.25.
What is Acticor Biotech SAS (ALACT) current market capitalization?
Acticor Biotech SAS market cap is approximately 3.88 million.
What is Acticor Biotech SAS (ALACT) Earnings Per Share (EPS)?
The trailing EPS is -€1.13.
Does Acticor Biotech SAS (ALACT) pay dividends?
No. Acticor Biotech SAS does not pay a dividend.
What is Acticor Biotech SAS (ALACT) beta (volatility) score?
Acticor Biotech SAS has a beta of -0.264, indicating lower volatility than the overall market.
